Revolution Medicines Inc (NASDAQ: RVMD) on Friday, plunged -3.90% from the previous trading day, before settling in for the closing price of $57.37. Within the past 52 weeks, RVMD’s price has moved between $20.51 and $62.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 11.11%. The company achieved an average annual earnings per share of 9.62%. With a float of $141.01 million, this company’s outstanding shares have now reached $164.67 million.
Let’s determine the extent of company efficiency that accounts for 378 employees. In terms of profitability, gross margin is -17912.67%, operating margin of -88031.94%, and the pretax margin is -76377.09%.
Revolution Medicines Inc (RVMD) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Revolution Medicines Inc is 16.05%, while institutional ownership is 88.58%. The most recent insider transaction that took place on Nov 15 ’24, was worth 146,523. Before that another transaction happened on Nov 13 ’24, when Company’s insider sold 16,666 for $58.65, making the entire transaction worth $977,509. This insider now owns 264,408 shares in total.
Revolution Medicines Inc (RVMD) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -1.14 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.88) by -0.27. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 9.62% per share during the next fiscal year.
Revolution Medicines Inc (NASDAQ: RVMD) Trading Performance Indicators
Revolution Medicines Inc (RVMD) is currently performing well based on its current performance indicators. A quick ratio of 14.24 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12043.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.59, a number that is poised to hit -1.00 in the next quarter and is forecasted to reach -4.04 in one year’s time.
Technical Analysis of Revolution Medicines Inc (RVMD)
Looking closely at Revolution Medicines Inc (NASDAQ: RVMD), its last 5-days average volume was 1.47 million, which is a jump from its year-to-date volume of 1.34 million. As of the previous 9 days, the stock’s Stochastic %D was 31.54%. Additionally, its Average True Range was 2.16.
During the past 100 days, Revolution Medicines Inc’s (RVMD) raw stochastic average was set at 71.93%, which indicates a significant increase from 51.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.82% in the past 14 days, which was higher than the 42.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $49.14, while its 200-day Moving Average is $40.46. However, in the short run, Revolution Medicines Inc’s stock first resistance to watch stands at $56.58. Second resistance stands at $58.02. The third major resistance level sits at $58.87. If the price goes on to break the first support level at $54.29, it is likely to go to the next support level at $53.44. Now, if the price goes above the second support level, the third support stands at $52.00.
Revolution Medicines Inc (NASDAQ: RVMD) Key Stats
Market capitalization of the company is 8.91 billion based on 168,219K outstanding shares. Right now, sales total 11,580 K and income totals -436,370 K. The company made 0 K in profit during its latest quarter, and -156,290 K in sales during its previous quarter.
